No Record Found
Sector
PharmaceuticalsOpen
₹4.54Prev. Close
₹4.33Turnover(Lac.)
₹0.06Day's High
₹4.54Day's Low
₹4.5452 Week's High
₹052 Week's Low
₹0Book Value
₹-5.13Face Value
₹10Mkt Cap (₹ Cr.)
9.23P/E
0EPS
0Divi. Yield
0No Record Found
No Record Found
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2019 | Mar-2018 |
|---|---|---|---|---|
Equity Capital | 19.74 | 19.74 | 19.74 | 19.74 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | -30.76 | -30.75 | -30.65 | -30.24 |
Net Worth | -11.02 | -11.01 | -10.91 | -10.5 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Revenue | 0 | 0 | 0 | 0 |
yoy growth (%) | 0 | 0 | 0 | 0 |
Raw materials | 0 | 0 | 0 | 0 |
As % of sales | 0 | 0 | 0 | 0 |
Employee costs | 0 | 0 | -0.03 | -0.03 |
| Y/e 31 Mar( In .Cr) | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Profit before tax | 0 | -0.09 | -0.08 | -0.25 |
Depreciation | 0 | 0 | 0 | 0 |
Tax paid | 0 | 0 | 0 | 0 |
Working capital | -0.03 | -0.01 | -0.01 | 0.01 |
Other operating items |
| Y/e 31 Mar | Mar-2021 | Mar-2020 | Mar-2018 | Mar-2017 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 0 | 0 | 0 | 0 |
Op profit growth | -96.06 | 12.55 | -66.14 | 4,126.06 |
EBIT growth | -96.06 | 12.55 | -66.14 | -921.77 |
Net profit growth | -95.93 | 12.57 | -66.27 | -1,344.04 |
No Record Found
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd SUNPHARMA | 1,692.75 | 81.54 | 4,06,147.43 | 753.53 | 0.95 | 5,566.68 | 101.44 |
Divis Laboratories Ltd DIVISLAB | 6,798.85 | 77.26 | 1,80,488.11 | 557 | 0.44 | 2,357 | 561.08 |
Cipla Ltd CIPLA | 1,503.55 | 23.37 | 1,21,452.44 | 1,210.53 | 1.06 | 4,495.16 | 411.56 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,576.85 | 60.89 | 1,21,051.42 | 551 | 0.17 | 2,567 | 224.34 |
Dr Reddys Laboratories Ltd DRREDDY | 1,200.8 | 18.57 | 1,00,220.42 | 387.3 | 0.67 | 4,602.9 | 377.57 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Director
Dushyant Kumar Singh
Company Secretary
N S Parameshwaran
Independent Director
Hawa Singh Chahar
Director & Chief Executive Officer
Dhruv Singh
Upper Kesalton,
Tallital,
Uttar Pradesh - 263001
Tel: 91-98718 62796
Website: http://www.mescopharma.com
Email: nsparameswaran@mescosteel.com; mescogroup@rediffma
D-153/A 1st Flr,
Okhla Industrial Are, Phase-I,
New Delhi-110020
Tel: 91-11-26812682
Website: www.skylinerta.com
Email: admin@skylinerta.com/virenr@skylinerta.com
Summary
Mesco Pharmaceuticals started commercial operations in Jun.91 by venturing into seed-marketing of bulk drugs and formulations with the objective of later establishing facilities for manufacture of bul...
Read More
Reports by Mesco Pharmaceuticals Ltd
What is the Mesco Pharmaceuticals Ltd share price today?
What is the Market Cap of Mesco Pharmaceuticals Ltd?
What is the PE and PB ratio of Mesco Pharmaceuticals Ltd?
What is the 52 Week High and Low of Mesco Pharmaceuticals Ltd?
What is the CAGR of Mesco Pharmaceuticals Ltd?
What is the shareholding pattern of Mesco Pharmaceuticals Ltd?
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016, BSE Enlistment Number (RA): 5016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.